Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.7072
+0.0160 (2.31%)
At close: Jul 14, 2026, 4:00 PM EDT
0.7150
+0.0078 (1.10%)
After-hours: Jul 14, 2026, 7:26 PM EDT
Humacyte Revenue
Humacyte had revenue of $495.00K in the quarter ending March 31, 2026, a decrease of -4.26%. This brings the company's revenue in the last twelve months to $2.02M, up 289.94% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M.
Revenue (ttm)
$2.02M
Revenue Growth
+289.94%
P/S Ratio
94.59
Revenue / Employee
$10,957
Employees
184
Market Cap
190.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Arcturus Therapeutics Holdings | 54.71M |
| Tonix Pharmaceuticals Holding | 17.56M |
| MediWound | 14.48M |
| Caribou Biosciences | 11.20M |
| Alpha Cognition | 10.83M |
| Equillium | 4.39M |
| Korro Bio | 3.84M |
HUMA News
- 11 hours ago - Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - GlobeNewsWire
- 27 days ago - Humacyte price target lowered to $1.25 from $1.50 at TD Cowen - TheFly
- 4 weeks ago - Humacyte Slides: Corporate presentation - Filings
- 4 weeks ago - Humacyte Transcript: Study result - Transcripts
- 4 weeks ago - Humacyte Press release: Study result - Filings
- 4 weeks ago - Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - GlobeNewsWire
- 4 weeks ago - Humacyte price target raised to $4 from $3 at H.C. Wainwright - TheFly
- 4 weeks ago - Humacyte 47.62M share Spot Secondary priced at $1.05 - TheFly